Tag:

Sanofi

Latest Headlines

Latest Headlines

Sanofi banks on Philippines to lead public Dengvaxia rollout

The high-stakes rollout of Sanofi's dengue vaccine, Dengvaxia, is slated this month in the private market, the lead executive for the product said, adding that a tender for 3 million doses is in advanced discussions in the Philippines for a public launch within weeks.

Big Pharma's new PCSK9, heart failure meds stuck in the slow lane. What gives?

In noting Q4 sales of Sanofi and Regeneron's brand-new PCSK9 med Praluent--€5 million, a far cry from analyst estimates of €41 million or more--Bernstein analyst Tim Anderson said the big shortfall "is likely to bring scrutiny, as yet another example of slow uptake of a new medicine."

As corporate restructuring looms, Sanofi's vaccines deliver in 2015

In the midst of a reshaping, Sanofi has identified its vaccines outfit, Sanofi Pasteur, as a core unit to the company's future. And despite the challenges impacting the company at the corporate level, the vaccines unit had some bright spots to talk up in reporting Q4 and 2015 results.

Sanofi scarce on turnaround details, but left a few needles in the Q4 haystack

If you expected a catalog of detail on Sanofi's turnaround plans with Tuesday's earnings release, think again.

Sanofi's outlook less than sunny as key diabetes franchise continues to sag

Sanofi delivered a good-news, bad-news set of fourth-quarter results: Earnings better than expected and solid growth in emerging markets, but shortfalls in overall revenue and operating profits. Its follow-up to big-selling Lantus, Toujeo, beat projections, but its long-anticipated cholesterol fighter, Praluent, brought in just a few million euros.

UPDATED: NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent

Amgen's Repatha is in a market brawl with Sanofi and Regeneron's Praluent as the competitors rush to sew up as many OKs around the world as possible for the new-gen cholesterol fighters following their FDA approval last year within weeks of one another. Now Amgen has pulled ahead in England after the country's drug pricing watchdog has both changed course to cover Repatha for some patients, while dealing its competitors a blow with a rejection for Praluent.

Scientists call for development of quick Zika tests as epidemic rages on

As the Zika epidemic rages on, health experts are calling for the development of blood tests that can quickly and accurately pinpoint the virus and shed light on an associated condition in infants.

Sanofi commits to developing Zika vax while other big players will evaluate

Sanofi says it intends to apply its decades of vaccine development work and manufacturing expertise in dengue fever to try to create a vaccine for Zika virus, the mosquito-borne disease that the World Health Organization this week called a global health emergency.

Sanofi says job cuts in France should not involve plant closures

Sanofi is looking to trim 600 jobs in France as part of new CEO Olivier Brandicourt's plan to squeeze €1.5 billion in annual costs. The drugmaker says it does not plan on closing any plants in France as part of the process, but that does not mean that its production network in the home country will escape unscathed. Brandicourt has also said he will "reshape" the manufacturing network as part of his overall reorganization of the company.

Sanofi's Brandicourt mulls pulling the plug on Merck JV: Bloomberg

Back in 1994, Merck and Pasteur Merieux Connaught--now Sanofi Pasteur--teamed up on a joint venture to develop and market vaccines in Europe. Now, as Sanofi chief Olivier Brandicourt reorganizes the French pharma's operations in a cost-cutting bid, the 21-year-old partnership could be on the chopping block.